The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Review for Medical and Pharmacological Sciences

• Publication date

  2016-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 27649656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA damage regulates ARID1A stability via SCF ubiquitin ligase in gastric cancer cells.

  2015cited by this paper
• De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells

  2014cited by this paper
• Inhibition of SENP5 suppresses cell growth and promotes apoptosis in osteosarcoma cells

  2014cited by this paper
• SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade

  2014cited by this paper
• Staging systems of hepatocellular carcinoma: a review of literature.

  2014cited by this paper
• Targeting ATR in DNA damage response and cancer therapeutics.

  2014cited by this paper
• SUMOylation of ATRIP potentiates DNA damage signaling by boosting multiple protein interactions in the ATR pathway

  2014cited by this paper
• Proteome-Wide Identification of SUMO2 Modification Sites

  2014cited by this paper
• Regulation of DNA damage responses by ubiquitin and SUMO.

  2013cited by this paper
• Inhibition of SENP6-Induced Radiosensitization of Human Hepatocellular Carcinoma Cells by Blocking Radiation-Induced NF-κB Activation

  2013cited by this paper
• DNA damage response: three levels of DNA repair regulation.

  2013cited by this paper
• Treatment of hepatocellular carcinoma: present and future

  2013cited by this paper
• Inhibition of SENP1 induces radiosensitization in lung cancer cells

  2013cited by this paper
• DNA damage sensing by the ATM and ATR kinases.

  2013cited by this paper
• Sumoylation and the DNA Damage Response

  2012cited by this paper
• SUMOylation in carcinogenesis.

  2012cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.

  2011cited by this paper
• SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression.

  2010cited by this paper
• SUMOylation and De-SUMOylation: Wrestling with Life's Processes*

  2009cited by this paper
• Overexpression of SENP5 in oral squamous cell carcinoma and its association with differentiation.

  2008cited by this paper
• Concepts in sumoylation: a decade on

  2007cited by this paper
• Modification in reverse: the SUMO proteases.

  2007cited by this paper
• Role of desumoylation in the development of prostate cancer.

  2006cited by this paper
• A Novel Link Between SUMO Modification and Cancer Metastasis

  2006cited by this paper
• Modification with SUMO

  2003cited by this paper
• SUMO in Cancer - Wrestlers Wanted

  2002cited by this paper
• Ubiquitin and proteasomes: Sumo, ubiquitin's mysterious cousin

  2001cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper

• Integrative analysis of the expression profile and prognostic values of SENP gene family in hepatocellular carcinoma

  2025cites this paper
• Protein post-translational modifications and tumor immunity: A pan-cancer perspective.

  2025cites this paper
• SENP5 promotes endometrial cancer cell growth by regulating β-catenin deSUMOylation to enhance GPX4-resistance to ferroptosis

  2025cites this paper
• SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  2024cites this paper
• Peptidylprolyl isomerase A guides SENP5/GAU1 DNA-lncRNA triplex generation for driving tumorigenesis

  2024cites this paper
• SUMO and the DNA damage response

  2024cites this paper
• Abnormal protein SUMOylation in liver disease: novel target for therapy

  2024cites this paper
• Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options

  2023cites this paper
• SENP5 promotes homologous recombination-mediated DNA damage repair in colorectal cancer cells through H2AZ deSUMOylation

  2023influential citation
• SUMOylation and DeSUMOylation: Prospective therapeutic targets in cancer.

  2023cites this paper
• The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer

  2022cites this paper
• Developments in molecular and advanced endoscopic imaging in esophageal cancer

  2022cites this paper
• Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma

  2022cites this paper
• Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment

  2022cites this paper
• Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases

  2022influential citation
• Epigenetic remodelling in human hepatocellular carcinoma

  2022cites this paper
• The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development

  2021cites this paper
• Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells

  2021cites this paper
• SUMOylation Wrestles With the Occurrence and Development of Breast Cancer

  2021cites this paper
• The post translational modification of key regulators of ATR signaling in DNA replication

  2021cites this paper
• SUMO proteases SENP3 and SENP5 spatiotemporally regulate the kinase activity of Aurora A.

  2021cites this paper
• Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma

  2021cites this paper
• Unique structural features of the adenylate kinase hCINAP/AK6 and its multifaceted functions in carcinogenesis and tumor progression

  2021cites this paper
• Identification and Validation of Esophageal Squamous Cell Carcinoma Targets for Fluorescence Molecular Endoscopy

  2021cites this paper
• SUMOylation in liver disease.

  2020cites this paper
• SUMO1 modification of histone H4 is involved in the pathogenesis of nodular lymphocyte predominant Hodgkin lymphoma

  2020cites this paper
• Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer.

  2020cites this paper
• ROS-triggered AMPK de-SUMOylation promotes Warburg effect in hepatocellular carcinoma cells

  2020cites this paper
• P53 suppresses SENP3 phosphorylation to mediate G2 checkpoint

  2020cites this paper
• SUMOylation homeostasis in tumorigenesis.

  2019cites this paper
• Progress in the Discovery of Small Molecule Modulators of DeSUMOylation.

  2019cites this paper
• Propofol activates autophagic activity of vascular endothelial cells by inhibiting SENP1 expression and attenuates vascular endothelial injury induced by ischemia-reperfusion in orthopedic surgery

  2019cites this paper
• Desumoylase SENP6 maintains osteochondroprogenitor homeostasis by suppressing the p53 pathway

  2018cites this paper
• The post-translational modification, SUMOylation, and cancer (Review)

  2018cites this paper
• Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.

  2018cites this paper
• HMTH1 induces the metastasis and recurrence of the parotid adenoma by repairing DNA damage.

  2018cites this paper
• Effect of luteolin on HepG2 liver cancer cell proliferation in vitro and angiogenesis activity

  2018cites this paper
• Caracterização genómica e epigenética de biópsias de carcinoma basocelular

  2018cites this paper
• The regulatory role of dopamine receptor D1 on PP2A via SUMO-1 modification.

  2017cites this paper
• The polymorphism of XRCC1 and coronary artery disease risk: a meta-analysis.

  2017cites this paper
• Ubiquitin-like modifications in the DNA damage response.

  2017cites this paper
• SUMOylation in cardiac disorders - a review.

  2017cites this paper
• SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.

  2017cites this paper
• The polymorphism of XRCC 1 and coronary artery disease risk : a meta-analysis

  year unknowncites this paper